Personal Care Products

Synergy CHC

Synergy CHC released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 5.493 M (forecast USD 8.334 M), actual EPS USD -0.2299 (forecast USD 0.03)

Synergy CHC released FY2025 annual earnings on April 1 Pre-Market EST, actual revenue USD 30.38 M (forecast USD 35.15 M), actual EPS USD -1.2699 (forecast USD 0.27)

Synergy CHC released FY2025 Q4 earnings on April 1 Pre-Market (EST), actual revenue USD 6.065 M (forecast USD 10.83 M), actual EPS USD -1.3152 (forecast USD 0.01)

Synergy CHC to release FY2025 Q4 earnings on March 31, 2026, pre-market EST; forecast revenue USD 10.83 M, EPS USD 0.01

Synergy CHC released FY2025 9 Months Earnings on November 13 Pre-Market (EST), actual revenue USD 24.32M, actual EPS USD 0.275

Synergy CHC released FY2025 Q3 earnings on November 13 Pre-Market EST, actual revenue USD 8.01 M (forecast USD 10.9 M), actual EPS USD 0.0099

Synergy CHC to Release FY2025 Q3 Earnings on November 13 Pre-Market EST, Forecast Revenue USD 10.9 M

Synergy CHC released FY2025 Semi-Annual Earnings on August 14 Pre-Market EST, with actual revenue of USD 16.31 M and EPS of USD 0.2687

Synergy CHC released FY2025 Q2 earnings on August 14 Pre-Market EST, actual revenue USD 8.135 M (forecast USD 10.8 M), actual EPS USD 0.165

Synergy CHC to release FY2025 Q2 earnings on August 14 Pre-Market EST, forecast revenue USD 10.8 M

Synergy CHC released FY2025 Q1 earnings on May 15 Pre-Market EST, actual revenue USD 8.171 M (forecast USD 9.025 M), actual EPS USD 0.1

Synergy CHC to Release FY2025 Q1 Earnings on May 15 Pre-Market EST, Forecast Revenue USD 9.025 M

Synergy CHC released FY2024 annual earnings on March 31 Pre-Market (EST), actual revenue 34.83 M USD (forecast 35.11 M USD), actual EPS 0.2799 USD

Synergy CHC released FY2024 Q4 earnings on March 31 Pre-Market (EST), actual revenue USD 10.27 M (forecast USD 10.55 M), actual EPS USD 0.0128

Synergy CHC to Release FY2024 Q4 Earnings on March 31, Pre-Market EST; Forecast Revenue 10.55 M USD

Synergy CHC released FY2024 9 Months Earnings on December 6 Pre-Market (EST), actual revenue USD 24.56M, actual EPS USD 0.2738

Synergy CHC released FY2024 Q3 earnings on December 6 Pre-Market (EST), actual revenue USD 7.126M, actual EPS USD 0.1062

Synergy CHC to Release FY2024 Q3 Earnings on December 6, Pre-Market EST

Synergy CHC released FY2023 Q4 earnings on September 16 (EST), with actual revenue of 13.22 M USD and EPS of 0.3752 USD

Synergy CHC released FY2023 Cumulative 3Q Earnings on September 16, 2024 (EST), with Revenue of 29.56M USD and EPS of 0.496

Agape ATP

Akanda

NewGenIvf

Co-Diagnostics

PicoCELA

Tradr 2X Long QBTS Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

Liminatus Pharma

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

SNYR

Synergy CHC Corp. (NASDAQ: SNYR) reported its Q1 2026 financial results, showing revenue of $5.49 million, down from $8.17 million in Q1 2025. The decline was attributed to the absence of $1.5 million in license revenue from 2025 and stock issues affecting online sales. Operating expenses rose to $4.54 million, leading to a loss from operations of $0.57 million and a net loss of $2.57 million, compared to a net income of $0.88 million in the previous year. SNYR shares fell by 1.6% to 30 cents.

Baystreet

Synergy Hesitates on Quarterly Numbers

FTXG

Synergy CHC reported Q1 2026 revenue of $5.49 million and a net loss of $2.57 million. The gross margin was 72.3%, with an adjusted diluted loss per share of ($0.23). The functional beverage segment generated over $650,000, with an annual run rate exceeding $4 million. Revenue declined from $8.17 million in Q1 2025, partly due to the absence of $1.5 million in license revenue. The company raised approximately $2.7 million post-quarter to support operations and growth.

TradingView

First Trust NASDAQ Food & Beverage

VG Consumer Stap

iShares US Consumer Staples ETF

Invesco Food & Beverage ETF

SPDR FD Consumer Staples

Synergy CHC Reports Q1 2026 Revenue $5.49M, Net Loss $2.57M; Beverage Run Rate >$4M

Earnings Watch

Synergy CHC | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 5.493 M

Synergy CHC pre-market down 10.65%; Immutep pre-market up 188.02%; Allbirds pre-market up 106.42%; Allied Gaming & ENT pre-market up 55.52%

Price Alert

Pre-market hot trades in US stocks: Synergy CHC pre-market down 10.65%, concerns over equity dilution suppress market optimism

Synergy CHC shares are trading higher after Ascendiant Capital maintained a Buy rating and raised its price target from $5 to $5.5

benzinga_article

Synergy CHC Corp. shares surged nearly 100% in after-hours trading following an S-8 filing registering 2.25 million shares. The company, focused on consumer health and wellness, aims to grow through product innovation and brand positioning. Despite a market cap of $6.5 million and a significant decline over the past year, shares jumped from $0.58 to approximately $1.15 after the filing. The stock has shown a negative price trend across all time frames.

Synergy CHC Shares Surge Nearly 100% In After-Hours Trading: What's Going On?

CMCT

Synergy CHC rose 105.11% in after-hours trading; CIM Commercial Trust fell 19.17% in after-hours trading; Perfect Moment rose 40.45% in after-hours trading; Sana Biotechnology rose 22.74% in after-hours trading; Gopro rose 20.87% in after-hours trading

Creative Media & Community Trust

U.S. stock night market opening fluctuations: Synergy CHC rose 105.11% in the night market; CIM Commercial Trust fell 19.17% in the night market

Synergy CHC rose 105.11% in after-hours trading; ELF Beauty rose 0.96% in after-hours trading, with a transaction volume of $4,770; Huantai Biotech fell 0.80% in after-hours trading, with a transaction volume of $30

U.S. stock night trading anomaly: Synergy CHC surged 105.11% in after-hours trading, with clear capital flow. What caused such volatility in market sentiment?

Synergy CHC(SNYR.US)